Estimates of COVID-19 deaths in Mainland China after abandoning zero COVID policy

Background: China witnessed a surge of Omicron infections after abandoning zero COVID strategies on December 7, 2022. The authorities report very sparse deaths based on very restricted criteria, but massive deaths are speculated. Methods: We aimed to estimate the COVID-19 fatalities in Mainland China until summer 2023 using the experiences of Hong Kong and of South Korea in 2022 as prototypes. Both these locations experienced massive Omicron waves after having had very few SARS-CoV-2 infections during 2020-2021. We estimated age-stratified infection fatality rates (IFRs) in Hong Kong and South Korea during 2022 and extrapolated to the population age structure of Mainland China. We also accounted separately for deaths of residents in long-term care facilities, which were prominent in Hong Kong. Results: IFR estimates in non-elderly strata were modestly higher in Hong Kong than South Korea and projected 987,455 and 811,571 maximal COVID-19 deaths, respectively, if the entire China population was infected. Expected COVID-19 deaths in Mainland China until summer 2023 ranged from 64,573 to 691,219 assuming 25-70% of the non-elderly population being infected and variable protection of elderly (from none to three-quarter reduction in fatalities). The main analysis (45% of non-elderly population infected and fatality impact among elderly reduced by half) estimated 199,223-249,094 COVID-19 deaths until summer 2023. Large uncertainties exist regarding potential changes in dominant variant, health system strain, and impact on non-COVID-19 deaths. Conclusions: The most critical factor that can affect total COVID-19 fatalities in China is the extent to which the elderly can be protected.

[1]  J. Ioannidis,et al.  Differential COVID-19 infection rates in children, adults, and elderly: Systematic review and meta-analysis of 38 pre-vaccination national seroprevalence studies , 2023, Journal of global health.

[2]  Benjamin Cowling The impact of ending ‘zero COVID’ in China , 2023, Nature Medicine.

[3]  J. Wakefield,et al.  The WHO estimates of excess mortality associated with the COVID-19 pandemic , 2022, Nature.

[4]  G. Leung,et al.  Modelling the adjustment of COVID-19 response and exit from dynamic zero-COVID in China , 2022, medRxiv.

[5]  Yongdai Kim,et al.  Identifying susceptibility of children and adolescents to the Omicron variant (B.1.1.529) , 2022, BMC Medicine.

[6]  M. Peiris,et al.  Population-based sero-epidemiological estimates of real-world vaccine effectiveness against Omicron infection in an infection-naive population, Hong Kong, January to July 2022 , 2022, medRxiv.

[7]  A. Nardone,et al.  Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies , 2022, PLoS medicine.

[8]  D. Contopoulos-Ioannidis,et al.  Age-stratified infection fatality rate of COVID-19 in the non-elderly population , 2022, Environmental Research.

[9]  E. Lau,et al.  Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study , 2022, The Lancet Infectious Diseases.

[10]  C. Anastassopoulou,et al.  Risk and severity of SARS-CoV-2 reinfections during 2020–2022 in Vojvodina, Serbia: A population-level observational study , 2022, The Lancet Regional Health - Europe.

[11]  M. Ajelli,et al.  Modeling transmission of SARS-CoV-2 Omicron in China , 2022, Nature Medicine.

[12]  M. Levitt,et al.  Comparison of pandemic excess mortality in 2020–2021 across different empirical calculations , 2022, Environmental Research.

[13]  G. French,et al.  Impact of Hospital Strain on Excess Deaths During the COVID-19 Pandemic — United States, July 2020–July 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[14]  J. Ioannidis Over- and under-estimation of COVID-19 deaths , 2021, European Journal of Epidemiology.

[15]  A. Pan,et al.  Epidemiology and determinants of obesity in China. , 2021, The lancet. Diabetes & endocrinology.

[16]  J. Ioannidis Precision shielding for COVID-19: metrics of assessment and feasibility of deployment , 2020, BMJ Global Health.

[17]  D. Asch,et al.  Variation in US Hospital Mortality Rates for Patients Admitted With COVID-19 During the First 6 Months of the Pandemic , 2020, JAMA internal medicine.

[18]  Zhanlian Feng,et al.  Long-term care system for older adults in China: policy landscape, challenges, and future prospects , 2020, The Lancet.

[19]  L. Chow Care homes and COVID-19 in Hong Kong: how the lessons from SARS were used to good effect , 2020, Age and ageing.

[20]  D. Cummings,et al.  Age-specific mortality and immunity patterns of SARS-CoV-2 infection in 45 countries , 2020, medRxiv.

[21]  D. Buckeridge,et al.  SeroTracker: a global SARS-CoV-2 seroprevalence dashboard , 2020, The Lancet Infectious Diseases.

[22]  Alan D. Lopez,et al.  Measuring the completeness of death registration in 2844 Chinese counties in 2018 , 2020, BMC Medicine.